Cardiovascular Surgery and Interventions
2020, Vol 7, Num 1 Page(s): 039-039
ACE-gene polymorphism, particularly "D/I", may play a role in the occurrence of COVID-19 pneumonia in hypertensive elderly patients | |
DOI: 10.5606/e-cvsi.2020.779 | |
Hakan Göçer1, Ahmet Barış Durukan2 | |
1Department of Cardiology, Medical Park Uşak Hospital, Uşak, Turkey 2Department of Cardiovascular Surgery, Medical Park Uşak Hospital, Uşak, Turkey |
|
Renin-angiotensin-aldosterone system has an
important role in the pathophysiology of high blood
pressure.[1] Also, angiotensin II and bradykinin are
vasoactive molecules with multiple acute and chronic
effects on the cardiovascular system.[1,2] As stated
in recent reports, COVID-19 pneumonia more
frequently occurs in COVID-19-positive hypertensive
elderly.[2] To the best our knowledge, COVID-19
pneumonia has a grave prognosis in hypertensive
and elderly patients. Angiotensin-converting enzyme
(ACE) genotype has been blamed for this course, and
although the interaction between COVID-19 and
ACE receptors interaction has been well defined, ACE
genotype polymorphism has not been fully elucidated,
yet.[3] In this infection, many researches and reports
have shown the effect of ACE insertion deletion (I/D)
gene polymorphism on risk, prognosis, and reaction
to treatment of many diseases such as hypertension,
heart failure, myocardial infarction, diabetes, diabetic
nephropathy, and cancer.[3] It is well-known that ACE
gene is located on chromosome 17 and polymorphism
consists of three types within the intron 16 (DD, ID, II)
and depends on heredity, ethnicity, and geographical
considerations.[4] Furthermore, D/I type has been
found more frequently in hypertension, diabetes, and
myocardial infarction.[4] Prognosis is more grave in this
genotype polymorphism. Our suggestion is that D/I
type ACE gene polymorphism should be a research
of interest for predicting prognosis and propensity of
COVID-19 infection in hypertensive elderly patients.
Declaration of conflicting interests
Funding |
|
1) Sun P, Lu X, Xu C, Wang Y, Sun W, Xi J. CD-sACE2 inclusion
compounds: An effective treatment for coronavirus disease
2019 (COVID-19). J Med Virol 2020. [Epub ahead of print
2) South AM, Diz DI, Chappell MC. COVID-19, ACE2, and
the cardiovascular consequences. Am J Physiol Heart Circ
Physiol 2020;318:H1084-H90.
|
|